Skip to main content Help with accessibility Skip to main navigation

Guidelines

Coronavirus guidance

Guidance to support primary care prescribers and pharmacists is available from the MLCSU Coronavirus guidance resource page. Links are provided to national resources and regional documents produced by MLCSU, RDTC, and SPS for use by Pan Mersey APC, LSCMMG, and GMMMG.

The list of resources will be updated as new material becomes available so please check back regularly for updates.

The Pan Mersey APC supports the use of COVID-specific guidance issued by NICE, and NHS England and NHS Improvement. During the COVID pandemic this will supersede any APC advice.

Documents

Date Added: 31 - Jan - 2018

The Pan Mersey Area Prescribing Committee recommends the use of adalimumab, certolizumab pegol, etanercept, golimumab, infliximab and secukinumab▼ in the management of ankylosing spondylitis (AS), and adalimumab, certolizumab pegol, golimumab and etanercept in non-radiographic axial spondyloarthritis (NRAxSpA) in accordance with NICE TA383, NICE TA407 and NICE TA497.

Prescribing pathway

Body System:
Date Added: 26 - Jun - 2019
Body System:
Date Added: 26 - Jun - 2019
Body System:
Date Added: 30 - Jul - 2020
Body System:
Date Added: 25 - Sep - 2019

Application form for providers to apply to commissioners for in-year funding .

Body System:
Date Added: 22 - May - 2019
Body System:
Date Added: 23 - Oct - 2020
Date Added: 30 - Nov - 2018

The Pan Mersey Area Prescribing Committee recommends that antipsychotics prescribed for BPSD should be initiated by a dementia specialist and reviewed in accordance with NICE/SCIE guidelines.

Body System:
Date Added: 18 - Sep - 2018

This Guidance does not include prescribing advice to primary care from secondary care specialists e.g. oral medicine, special care dentistry or oral and maxillofacial surgery, regarding the management of complex conditions and patients with multiple co-morbidities.

Body System:
No RAG
Date Added: 27 - Nov - 2009

 

NICE Bites – Depression
Published 27th November 2009, updated 23rd July 2017 · North West Medicines Information Centre

Body System:
No RAG
Date Added: 30 - Oct - 2015

 

NICE Bites – Type 1 diabetes
Published 30th October 2015, updated 23rd July 2017 · North West Medicines Information Centre

NICE Bites – Type 2 diabetes
Published 4th February 2016, updated 23rd July 2017 · North West Medicines Information Centre

NICE Bites – Diabetes (type 1 and 2) in children and young people
Published 26th November 2015, updated 23rd July 2017 · North West Medicines Information Centre

Body System:
Date Added: 27 - Jun - 2017
Body System:
Date Added: 30 - Nov - 2018

Pharmacological treatment pathway 2018

Body System:
No RAG
Date Added: 26 - May - 2017
Body System:
Date Added: 30 - Jul - 2020
Body System:
Date Added: 01 - Nov - 2018
Body System:
Date Added: 30 - Nov - 2018

The Pan Mersey Area Prescribing Committee recommends the prescribing of biologic agents, by specialists only, for Juvenile Idiopathic Arthritis (JIA) as per NICE TA373 and TA238 in adult and paediatric services.

Body System:
Date Added: 30 - Jun - 2014

 

NICE Bites – Lipid modification
Published 5th August 2014, updated 23rd July 2017 and 6th October 2020 · North West Medicines Information Centre

Body System:
Date Added: 25 - Jul - 2017

The Pan Mersey Area Prescribing Committee recommends the prescribing of anti-TNF (adalimumab, certolizumab, etanercept, golimumab, infliximab) by specialists only, for inflammatory monoarthritis or oligoarthritis as specified.

MONOARTHRITIS or OLIGOARTHRITIS pathway

Body System:
Date Added: 27 - Mar - 2019

University Hospital Aintree Sleep Service Pathway

Body System:
Date Added: 30 - Nov - 2018

This guideline is for use in primary care for initial management, not in specialist pain service settings.

Body System:
Date Added: 14 - Aug - 2018

This document aims to discourage the inappropriate initiation and prescribing of opioids and gabapentinoids for non-neuropathic, non-palliative chronic pain.

Body System:
Date Added: 26 - Apr - 2018

If a private consultation identifies a long-term condition or a need for medication which is available as routine NHS treatment, this should be provided as such by the patient's usual primary care prescriber if they are satisfied it is appropriate, and the private provider issues the first prescription.

Date Added: 23 - Sep - 2020

The Pan Mersey Area Prescribing Committee recommends the sequential use of biological agents, adalimumab, brodalumab, certolizumab, etanercept, guselkumab, infliximab, ixekizumab, secukinumab, tildrakizumab and ustekinumab, in the management of psoriasis according to the attached flowchart.

Body System:
Date Added: 28 - Nov - 2018

The Pan Mersey Area Prescribing Committee recommends the sequential use of high cost agents, adalimumab, apremilast▼, certolizumab, etanercept, golimumab, infliximab, ixekizumab▼, secukinumab▼, tofacitinib▼ and ustekinumab in the management of psoriatic arthritis (PsA) in accordance with the recommendations below, and the accompanying flowchart.

PSORIATIC ARTHRITIS and PERIPHERAL SPONDYLOARTHROPATHY: high cost drugs pathway

Body System:
Date Added: 20 - Dec - 2018

Failure of intensive therapy with a combination of standard DMARDs (usually methotrexate, hydroxychloroquine and sulphasalazine) and DAS28 > 5.1

Body System:
Date Added: 02 - Nov - 2018

The Pan Mersey Area Prescribing Committee recommends the prescribing of anakinra, etanercept, infliximab or tocilizumab in Adult Onset Still’s Disease.

STILL'S DISEASE, adult onset (AOSD): pathway for the management of

Body System:
Date Added: 31 - Jan - 2019

The Pan Mersey Area Prescribing Committee recommends that psychotropic drugs in people with a learning disability, autism or both should be reviewed and reduced in primary care in line with NHS England (NHSE) guidelines. Psychotropics should be initiated by a learning disability specialist.

Body System:
Date Added: 29 - Jul - 2020
Body System:
Date Added: 14 - Aug - 2018

Pan Mersey Area Prescribing Committee recommends that prescribers should NOT supply treatment durations in excess of THREE MONTHS for patients who are going to live or travelling abroad or otherwise absent from the UK. Patients should make local arrangements in their country of residence for on-going medical care.

Static

Date Added: 28 - Feb - 2018

This document is a good practice guide to support prescribers with prescribing unlicensed and “off-label” medicines. It describes the differences between licensed medicines, unlicensed medicines and “off-label” medicines. It advises prescribers on a stepped approach when considering what to prescribe, and highlights the prescriber’s responsibilities and best practice around patient communication.